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  1ABSTRACT 
The studies outlined in this honor’s thesis were designed to better understand the 
mechanisms at both the cellular and molecular levels associated with the onset of 
osteoarthritis.  The horse was used as a model organism, and the experiments were 
performed on normal equine chondrocytes cultured   in   vitro.  Interleukin-6 (IL-6) and 
interleukin-8 (IL-8) are known to have catabolic effects on the cartilage matrix while 
osteogenic protein-1 (OP-1) is a known anabolic factor.  There is no complimentary 
information regarding the effects of these peptides on small G-protein (Cdc42, Rac, and 
Rho) activation in articular chondrocytes. The objectives of the present study were to 
determine the activation status of Cdc42, Rac, and Rho after treatment with IL-6, IL-8, 
or OP-1.  The G-proteins play an important role in the maintenance of the actin 
cytoskeleton and chondrocyte phenotype, so they are of interest because of their clinical 
relevance in regards to osteoarthritis.  To determine a suitable dose for use in these 
activation assays, chondrocytes were treated in vitro with varying concentrations of IL-
6, IL-8, or OP-1, and changes in RNA transcripts of MMP-3, MMP-13, Col2A1, and 
Aggrecan were quantified using RT-PCR.  In the case of IL-6, IL-8, and OP-1, it was 
determined that a dose of 100ng/mL media stimulated catabolism/anabolism. 
Chondrocytes were also examined using confocal microscopy following treatment with 
IL-6, IL-8, or OP-1 to determine if a correlation exists between the normal vs 
fibroblastic phenotypes and the activation status of the small G-proteins.   
Our initial hypothesis was that IL-6 and IL-8 would increase Cdc42 and Rac and 
decrease Rho activity, while OP-1 would have an opposite effect.  Activity of the small 
G-proteins was determined through an affinity binding assay and subsequent western 
analysis.  To date, our experiments indicate that treatment of the chondrocytes with IL-6 
and IL-8 resulted in a decreased activity status of Cdc42 and Rac, which is contrary to 
the initial hypothesis.  Studies to determine the effects of OP-1 and the activation status 
of Rho in response to all treatments are nearing completion.   
 
  2INTRODUCTION 
Articular Cartilage and Osteoarthritis 
  Chondrocytes are the resident cells of articular cartilage and are responsible for 
the generation and maintenance of the collagen and proteoglycan components of the 
extracellular matrix (ECM).
1 Interactions between chondrocytes and the ECM are 
fundamental to the maintenance of normal cartilage phenotype.  The cell is isolated 
within the ECM which is neither vascularised nor innervated, and nutrient/waste 
exchange occurs through diffusion.  The chondrocyte rises to clinical prominence in the 
case of articular cartilage because these properties predispose the tissue to degenerative 
conditions, the most common being osteoarthritis (OA).
2  Although OA may affect 
juveniles, it is more associated with the older population such that most people of 70 
years of age will have some symptoms of the disease. In fact, the clinical syndrome of 
osteoarthritis is one of the most common causes of pain and disability in middle-aged 
and older people.   
The phenotypic expression of chondrocytes is in part controlled through 
regulation or modulation of the actin cytoskeleton.  Chondrocytes expressing normal 
phenotype are generally polyhedral and have a cortical rim of actin while loss of 
phenotype is associated with a fibroblastic shape and cytosolic actin stress fiber 
formation.  This correlation between the organization of the actin cytoskeleton and 
chondrocyte phenotype is important for understanding the maintenance of the 
chondrocyte phenotype and cartilage metabolism. 
3  
 
  3GTPase proteins 
The small G-proteins Cdc42, Rac, and Rho regulate signaling cascades involved 
in organization of the actin cytoskeleton, cell cycle control, gene expression and cell 
migration.
4-8  The G-proteins cycle between an active, GTP-bound state, and an 
inactive, GDP-bound state. Under normal physiological conditions, GTPases are GDP-
bound and inactive. Once the cell is stimulated, the GTPase will release GDP and bind 
GTP.  This process is catalyzed by guanine nucleotide exchange factors (GEFs). Once 
activated, GTPases interact with a variety of effecter proteins to promote cellular 
responses.  GTPases are turned off by GTPase-activating proteins (GAPs) which 
stimulate the hydrolysis of GTP to GDP.  Only in the GTP-bound form can these G-
proteins communicate with signal transduction cascades and alter cell morphology.  A 
major role of the GTPases is to interact with cellular target proteins and impact the 
reorganization and maintenance of the actin cytoskeleton.  The G-proteins are 
associated with specific phenotypic alterations of the actin cytoskeleton such as stress 
fibers and focal adhesions (Rho), veil-like lamellipodial (Rac), and filopodial 
microspikes (Cdc42).
4, 5, 7, 9-11
Because of their role in regulation of the actin cytoskeleton, G-proteins are of 
particular interest in the understanding of OA because their regulation will ultimately 
alter cell morphology and phenotypic expression. 
 
Interleukin-6 (IL-8) and Interleukin-8 (IL-8)  
 The  proinflammatory
 cytokines interleukin-6 (IL-6) and interleukin-8 (IL-8) 
are major regulators of the inflammatory response and have been identified as 
  4pathogenic factors in a number of different tissues.
12, 13 Current research suggests that 
these cytokines are released in response to acute inflammation and exert a biological 
effect on the cell through cell-surface receptors.
14, 15  In the joint, regulation of these 
catabolic compounds plays an important role in the progression of osteoarthritis (OA), 
and understanding their role in chondrocyte physiology is therefore of significant 
clinical importance.
3, 5, 12, 13, 16-18 The mechanism by which these cytokines affect 
cartilage and chondrocyte physiology has not yet been extensively studied. 
 
Osteogenic Protein-1 (OP-1)/ Bone morphogenetic protein-7 (BMP-7) 
Several studies in a variety of both in vitro tissue culture and in vivo animal models 
have examined the anabolic effects of OP-1 on bone formation and cartilage regulation 
and maintenance.  These studies have shown that OP-1 is expressed in normal articular 
cartilage, and that it is responsible for stimulating matrix synthesis in chondrocytes.
19-22  
In vitro studies have demonstrated that OP-1 inhibits terminal chondrocyte 
differentiation.  This terminal differentiation would otherwise result in chondrocyte 
hypertrophy and mineralization, which alters the phenotype of the chondrocyte.   
Together, these studies suggest that OP-1 preserves the normal chondrocyte 
phenotype.
23  This action opposes the effects of the interleukins, and the mechanism of 
this inhibition remains unknown.   
  Understanding the roles and regulations of these three peptides will further the 
overall understanding of chondrocyte biology and thereby further elucidate the 
mechanisms associated with the cellular onset of OA. 
 
 
  5METHODS 
The Cellular Model 
Equine (Equus equus) chondrocytes were used as a cellular model for these 
experiments.  Cartilage samples were harvested from donated research horses, and the 
chondrocytes were isolated from the harvested cartilage as previously described.
24  A 
digestion medium was used which consisted of 0.075% collagenase in F-12 complete 
medium (F-12 containing 10% fetal bovine serum (FBS), HEPES buffer, L-glutamine, 
α-ketoglutaric acid, ascorbic acid, penicillin, and streptomycin). Ten mLs of collagenase 
medium was added per gram of cartilage, and digestion was carried out for 12 hours at 
37
oC. The cell suspension was filtered through a sterile funnel containing a base layer 
of 44 µm mesh and 4 layers of cheesecloth.  The cells were pelleted, resuspended in 
medium, and stored in liquid nitrogen for the experiments described below.   
 
Histology 
Chondrocytes were grown in monolayer on cover slips at 50% confluence, 
treated with IL-6 (100 ng/ml), IL-8 (100 ng/ml), or OP-1 (100 ng/mL) for 0, 2, or 30 
minutes, and fixed in 4% paraformaldehyde. Chondrocytes were subsequently 
incubated with 0.1% Triton and then 7% BSA to block non-specific antibody binding. 
  The actin cytoskeleton was stained with Alexa Fluor 488 phalloidin (Invitrogen, 
Carlsbad, CA), and the nucleus was identified with To-PRO-3 nucleic acid stain 
(Invitrogen). The cover slips were mounted with ProLong Gold antifade reagent 
(Invitrogen), and the cells were visualized using confocal microscopy as previously 
described.
11
  6Dose Response 
Chondrocytes from horses 8-18 months old were plated at 80% confluence and 
grown at 37
oC in F-12 complete media with 10% FBS for 48 hrs. The medium was 
changed on day 2 to defined DMEM/F-12 and mini-ITS (5nM insulin, 2ug/mL 
Transferrin, 2ng/mL Selenous Acid, 25ug/mL Ascorbic Acid, 420ug/mL BSA, 2.1 
ug/mL linoleic acid).
22  On day 2, cells were treated with IL-6 (10, 50, or 100 ng/mL 
media), IL-8 (10, 50, or 100 ng/mL media), or OP-1 (50, 100, or 150 ng/mL media).  
This range of doses was examined for IL-6, IL-8 or OP-1 based on the doses examined 
in previous literature.  The medium was exchanged on day 4 with the same treatment.  
On day 6, the media was removed, the cells were rinsed with PBS, lysed with Trizol, 
and total RNA was extracted.    The IL-6 and IL-8 used for these studies was obtained 
from R & D Systems, Minneapolis, MN, and the OP-1 was obtained from Stryker 
Biotech, Hopkinton, MA. 
  Real-time quantitative PCR assays were then performed to assess changes in 
transcript levels of the matrix metalloproteinases 3 and 13 (MMP-3 and MMP-13), 
aggrecan, and collagen type IIb (Col2A1).  Total RNA was reverse transcribed and 
amplified by use of a one-step system with sequence detection software (Applied 
Biosystems version 2.0, Foster City, CA).  The primers and dual-labeled fluorescent 
probes (6-carboxyfluorescein [6-FAM] as the 5′ label [reporter dye] and 
tetramethylrhodamine [TAMRA] as the 3′ label [quenching dye]) were designed with 
Primer Express Software Version 2.0b8a (Applied Biosystems, Foster City, CA) and 
using equine sequences published in GenBank, sequenced in our laboratory, or obtained 
from Dr. Alan Nixon (Comparative Orthopaedics Laboratory, Cornell University, 
  7Ithaca, NY).  Gene expression of these compounds was assessed relative to the 
transcript levels of 18S RNA using the 2
-ddCt method as previously described.
25
 
Affinity Binding Assay 
Chondrocytes from horses 8-18 months old were plated at 100% confluence and 
grown in F-12 complete media with 10% FBS for 48 hrs. The medium was changed on 
day 2 to defined DMEM/F-12 and mini-ITS.  On day 3, cells were treated with IL-6, IL-
8, or OP-1 at 100 ng/mL media for 0, 2 or 30 minutes.  The cells were rinsed with 1X 
PBS, and lysed using pGEX lysis buffer (1% Triton, 20 mM HEPES, 51 mM EDTA, 
1.0 mM DTT, 15 mM NaCl, 1 mM NaN3, 1.2 mM PMSF, 1 µg/ml aprotonin, 1 µg/ml 
leupeptin, 0.1 µM GDP, pH 8.0) for the Cdc42/Rac assay or rinsed with 1 X TBS, and 
lysed with Mg
2+ lysis buffer (10% glycerol, 5% NP-40, 750 mM NaCl, 50 mM MgCl2, 
5 mM EDTA, 125 mM HEPES, 1 µg/ml aprotonin, 1 µg/ml leupeptin, 1.0 mM PMSF, 
pH 7.5) for the Rho assay as described previously.
6, 11, 26  The resultant chondrocyte 
lysates were utilized for the affinity binding assays as described below.   
  To generate positive and negative controls, cos 7 cells were transfected as 
described previously with plasmid DNA using FuGENE 6 according to the 
manufacturer’s direction (Boehringer Mannheim, Mannheim, Germany).
27  
Hemagglutinin-tagged pcDNA3 plasmids expressing wild type Cdc42, Rac, or RhoA, 
constitutively active Cdc42(Q61L), Rac(G12V), or RhoA(G14V), or dominant-negative 
Cdc42(T17N), Rac(T17N), or RhoA(T19N) were used.   
  8Pulldown Assay for Cdc42 and Rac 
To determine Cdc42 and Rac activity, an affinity-binding assay was performed 
using the cell lysate prepared as outlined above.  The downstream target of Cdc42, p21-
binding domain (PBD) of p21-activating kinase-1, was expressed in pGEX plasmid in 
Escherichia coli, purified, and coupled to glutathione-agarose beads as previously 
described.
28, 29   
The chondrocyte lysates were subjected to centrifugation at 5,000 × g for 1 
minute at 4
oC, and the total protein content was quantified using the Bradford method.  
Equal protein contents (1.0 mg) from each sample were loaded onto PBD beads to 
selectively retain GTP-Cdc42.
28, 29 The lysate/bead mixture was rocked for 30-45 
minutes at 4
oC, centrifuged, and rinsed three times with pGEX lysis buffer to remove 
unbound proteins from the suspension.  Western blot loading dye was then added to the 
final pellet, and the beads were boiled for 5 minutes to release the retained Cdc42 and 
Rac.  Samples were resolved by 15% SDS-PAGE and transferred to polyvinylidene 
fluoride membranes. The membranes were blocked with 5% milk and then probed with 
a primary mouse antibody to either Cdc42 or Rac (BD Biosciences, Palo Alto, CA).   
Secondary antibodies of horseradish peroxidase-coupled sheep anti-mouse were used to 
detect the primary antibody with enhanced chemiluminescence (ECL) reagent, and the 
resultant chemiluminecence was quantified using a Chemi-Doc station with Quantity 
One software (Bio-Rad, Richmond, CA).   A ratio of retained active: total (GTP: total 
(GTP+GDP)) at times 0, 2, and 30 minutes ([GTP/(GTP+GDP)]t0, 
[GTP/(GTP+GDP)]t2, [GTP/(GTP+GDP)]t30) was calculated, and the ratios were 
normalized to t0=1.0 for comparison between treatments.   
  9Pulldown Assay for Rho 
Glutathione-agarose beads were created and tagged with the Rho binding 
domain (RBD) of the downstream target, Rhotekin (TRBD) as described.
30, 31  Equal 
protein contents of 4mg were loaded with the RBD beads (using the same protocol as 
described for Cdc42 and Rac), the samples were resolved with PAGE, transferred to a 
PVDF membrane, and a monoclonal antibody to Rho (BD Biosciences, San Jose, CA) 
was used to detect Rho and a ratio of retained active:total (GTP: total (GTP+GDP)) was 
calculated.   
 
RESULTS  
Histology 
Chondrocytes were observed using confocal microscopy to evaluate the actin 
cytoskeleton after treatment with IL-6, IL-8 or OP-1. Untreated, control chondrocytes 
demonstrated a defined cortical rim, minimal stress fibers, and a polyhedral shape 
[Figure 1]. With 2 minutes of IL-6 and IL-8 treatment, cells developed cytosolic stress 
fibers, which remain after 30 minutes of treatment. The increase in stress fibers is 
indicative of Rho activation.
4  Cells treated with OP-1 at 2 minutes appeared round with 
a defined cortical rim of actin. The chondrocytes remained in this state after 30 minutes 
OP-1 treatment [Figure 1]. 
  
Dose Response 
As outlined above, chondrocytes were treated with IL-6 (10, 50, or 100 ng/mL 
media), IL-8 (10, 50, or 100 ng/mL media), or OP-1 (50, 100, or 150 ng/mL media).  
  10RNA expression of Collagen type IIb (Col 2A1) [Figure 2] was unaffected by treatment 
with IL-6, IL-8, or OP-1.  The catabolic matrix metalloproteases, MMP-13 [Figure 3] 
and MMP-3 [Figure 4], were increased with treatment of IL-6 at 100ng/mL, IL-8 at 50 
and 100ng/mL, and OP-1 at 50 ng/mL.  Aggrecan [Figure 5] expression was increased 
after treatment with IL-6 at 100 ng/mL and OP-1 at 100 ng/mL.  Due to inter-animal 
variability, more trials are in progress to verify these findings.  Based on this 
preliminary data, a dose of 100ng/mL media was utilized for the affinity binding assays 
with IL-6, IL-8, or OP-1. 
 
Activation Status of G-Proteins 
Cdc42- Cdc42 activity [Figure 6-7] was normalized to 1.0 among all no treatment 
controls for comparison to either IL-6 or IL-8.  IL-6 treatment (2 minutes) resulted in a 
significant decrease in active, GTP-bound Cdc42 compared to the no treatment control 
(mean 55.9%, range 10.0%-84.3%; p=0.05).  After 30 minutes of IL-6 treatment, Cdc42 
activity remained significantly decreased (mean 51.3%, range 31.9-79.1%; p=0.05). 
There was no difference in Cdc42 activity between 2 and 30 minute treatment time 
points.  IL-8 had a similar effect on Cdc42 activation status. There was a significant 
decrease in Cdc42 activation status after 2 minutes of treatment (mean 56.7%, range 
21.0-81.7%; p=.05).  There were no significant differences in Cdc42 activity between 2 
and 30 minute time points. 
Rac- Rac activity [Figure 8-9] was normalized to 1.0 among all no treatment controls 
for comparison to either IL-6 or IL-8. IL-6 treatment (2 minutes) resulted in a 
significant decrease in active, GTP-bound Rac compared to the no treatment control 
  11(mean 70.9%, range 12.3%-86.4%; p=0.1). After 30 minutes of IL-6 treatment, Rac 
activity remained significantly decreased (mean 56.3%, range 21.7-64.1%; p=0.1). 
There was no difference in Rac activity between 2 and 30 minute treatment time points. 
IL-8 had a similar effect on Rac activation status. There was a significant decrease in 
Rac activation status after 2 minutes of treatment (mean 53.6%, range 40.3-63.4%; 
p=0.1). There were no significant differences in Rac activity between 2 and 30 minute 
time points. There is a significant decrease in GTP-Rac in response to both cytokines at 
both 2 and 30 minutes.   
Rho-RBD pulldowns are in progress for treatments with IL-6, IL-8, and OP-1. 
 
DISCUSSION 
The roles of IL-6, IL-8, and OP-1 on cartilage catabolism and anabolism, 
respectively, have been previously established.
13, 18, 19, 21-23, 32, 33  In the present study, we 
sought to determine the effects of these cytokines on the activation status of the small 
G-proteins—Cdc42, Rac, and Rho.  The effects of IL-6 and IL-8 in regulation of these 
small G-proteins were explored as potential molecular mechanisms responsible for the 
loss of chondrocyte phenotype and degradation of the cartilage matrix.  The RhoA 
subfamily of small G-proteins were investigated due to their previously described 
effects on actin cytoskeleton organization and thus the regulation of chondrocyte 
phenotype.
4, 10, 34, 35  Reconciling these results with those of other studies will increase 
the understanding of these mechanisms and may lead to novel treatments of articular 
cartilage deterioration and arthritis.   
  12Previous studies in our lab have examined the role of insulin-like growth factor-I 
(IGF-I), an anabolic compound, on articular chondrocytes.  These studies suggest that 
IGF-I diminishes active, Cdc42 and Rac, and preserves the normal chondrocyte 
phenotype.
26, 28  
The findings of the present study suggest that both IL-6 and IL-8 diminish the 
activation status of Cdc42 and Rac.  The histological findings demonstrate that after 
exposure to IL-6 and IL-8, a normal chondrocyte loses its polyhedral shape and assumes 
a more elongated, fibroblastic morphology with inherent cytosolic stress fibers and loss 
of the cortical rim of actin.  These findings for IL-6 and IL-8 are in agreement with the 
results of other studies examining the impact of the closely related cytokine, IL-1.
3, 16, 17, 
33, 36  
It is difficult to reconcile the results of the Cdc42 and Rac activation studies with 
the histological results because in the case of both IGF-I and IL-6 and IL-8, the 
activation status of Cdc42 and Rac are diminished, but there are substantially different 
histological findings.  After treatment with IGF-I, the normal chondrocyte phenotype is 
preserved, while treatment with IL-6 and IL-8 results in a loss of the normal 
morphology.  It is unclear why diametrically opposing mediators such as IL-6, IL-8, and 
IGF-I have the same effect on Cdc42 and Rac activation.  Since the signaling networks 
that regulate cellular metabolism following cytokine stimulation are complex and 
involve a number of converging and diverging pathways, it is probable that these 
peptides activate parallel networks to generate distinct signaling pathways that are 
converging at some point at an upstream target of Cdc42 and Rac.  Furthermore, it is 
  13likely that the underlying cellular signaling is a very rapid event, and so the timing of 
the experiments is of utmost importance which might explain the difference between the 
histological findings and the results of the activation study.
4, 11, 26  Further studies to 
elucidate the upstream pathways from cell surface receptor to Cdc42 and Rac should 
provide additional information regarding the role of the small G-proteins in chondrocyte 
phenotypic control and therefore cartilage matrix regulation.  
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  20FIGURE LEGENDS  
Figure 1. Chondrocytes stained with Alexa Fluor 488 phalloidin (blue) to visualize the 
actin cytoskeleton and To-PRO-3 (red) to visualize nucleic acid with confocal 
microscopy. Control chondrocytes [A] show a defined cortical rim, minimal stress 
fibers, and tetrahedral shape. IL-6 [B] and IL-8 [C] treated cells demonstrate a less 
defined rim and increased number of stress fibers. OP-1 treated cells [D] show a more 
defined rim and rounded appearance. 
 
Figure 2.  Chondrocytes were treated with IL-6 (10, 50, or 100 ng/mL), IL-8 (10, 50, or 
100 ng/mL), or OP-1 (50, 100, or 150 ng/mL), and Col2b expression levels were 
quantified relative to the expression of 18S (which is indicative of the relative amount 
of total RNA).  The values were normalized with respect to the no treatment group.   
 
Figure 3. Chondrocytes were treated with IL-6 (10, 50, or 100 ng/mL), IL-8 (10, 50, or 
100 ng/mL), or OP-1 (50, 100, or 150 ng/mL), and Col2b expression levels were 
quantified relative to the expression of 18S (which is indicative of the relative amount 
of total RNA).  The values were normalized with respect to the no treatment group.   
 
Figure 4. Chondrocytes were treated with IL-6 (10, 50, or 100 ng/mL), IL-8 (10, 50, or 
100 ng/mL), or OP-1 (50, 100, or 150 ng/mL), and Col2b expression levels were 
quantified relative to the expression of 18S (which is indicative of the relative amount 
of total RNA).  The values were normalized with respect to the no treatment group.   
 
  21Figure 5. Chondrocytes were treated with IL-6 (10, 50, or 100 ng/mL), IL-8 (10, 50, or 
100 ng/mL), or OP-1 (50, 100, or 150 ng/mL), and Col2b expression levels were 
quantified relative to the expression of 18S (which is indicative of the relative amount 
of total RNA).  The values were normalized with respect to the no treatment group.   
 
Figure 6. Activation status of Cdc42 in articular chondrocytes detected by Western blot 
analysis using a monoclonal Cdc42 antibody.  The top row represents only active, GTP-
bound Cdc42 in no treatment controls (NT) and chondrocytes treated with IL-6 or IL-8 
for 2 or 30 minutes.  The bottom row represents whole cell lysate (WCL) which 
contains both GTP and GDP-bound Cdc42 and serves as a loading control for the PBD 
assay.  This Western blot is representative of 4 individual experiments. 
 
Figure 7.  The mean ratio of GTP-Cdc42:total Cdc42 from n=4 experiments (+/- SE).   
Experiments were performed independently and using chondrocytes from three 
different animals.  The no treatment control (NTC) value is set to 1 and all values are 
expressed as relative to the NTC.   
 
Figure 8.  Activation status of Rac in articular chondrocytes detected by Western blot 
analysis using a monoclonal Rac antibody.  In each whole cell lysate (WCL) the 
expression of total Rac (GTP and GDP bound) was similar, serving as a loading control 
for the PBD assay.   
 
  22 Figure 9.  The mean ratio of GTP-Rac:total Rac from n=3 experiments (+/- SE).     
Experiments were performed independently and using chondrocytes from three 
different animals.  The no treatment control (NTC) value is set to 1 and all values are 
expressed as relative to the NTC.   
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